Where We Stand: AMCP does not support direct‐to‐consumer advertising that promotes specific prescription drug products, however we do support advertisements that educate the public about disease symptoms and available treatment options.
Where We Stand: AMCP supports compensation for pharmacists providing direct patient care services. Services provided by pharmacists are a vital part of comprehensive patient care, especially when delivered in collaboration with other health care providers.
Where We Stand: AMCP supports efforts to encourage transparency within health care. This statement focuses on how transparency applies to the use of prescription information, drug costs and communication.
Press Release: According to a newly released survey from AMCP, nearly 63 percent of Medicare beneficiaries say they would recommend MTM services provided under the Part D prescription drug program to friends and relatives.
On March 1, 2019, AMCP provided comments to CMS in response to its 2020 for Medicare Part D Call Letter. AMCP offered comments on the following sections of the notice; Part D Benefit Parameters for Non-Defined Standard Plans; Formulary Submissions; Medication Therapy Management (MTM); and Part D Mail Order Auto-Ship Modifications.